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cell loss after processing. One method of minimizing cell loss
during processing is to deplete plasma (PD) but not red blood cells.
Average loss of less than 0.1% nucleated cells was found in the
discarded plasma fraction after PD UCB processing (n  27).
Eighteen thousand racially diverse PD UCB units are now avail-
able on stem cell registries; however, clinical outcome for HSCT
using PD UCB products is unavailable. A retrospective analysis of
all patients with engraftment or survival data up to April 2005 was
performed on 118 HSCT using PD UCB (“All”). When patients
with prior transplants or transplanted during relapse were excluded
in the engraftment and survival analysis, this subset had 98 remis-
sion ﬁrst transplant patients (“Remission Patients”). The charac-
teristics for the 118 transplants were: median age 8 years old, range
0.3–55, 31 transplants 	16 years old (26%); median weight 26 kg,
range 4.5–103, 36 transplants 	50 kg (31%); male 61%; median
no. HLA ABDR matches 4.0; median TNC dose 5.6  107/kg
(n 118); transplant center reported median post-thaw TNC dose
5.2 107/kg (n 68); median CD34 dose 1.8 105/kg; malignant
indications 75%; transplants outside U.S. 35%; double transplant
16%; and non-myeloablative 8%. The incidence of grade III-IV
acute GVHD and extensive chronic GVHD among all patients
were 15% and 13%, respectively. For all patients, the median time
to engraftment for ANC 500 (n  87), platelet 20 K (n  72) and
50 K (n 68) were 22.0 (range 7–64), 49.5 (range 13–95), and 58.5
days (range 21–132), respectively. Unadjusted cumulative inci-
dence of ANC500 and platelet 20 K and 50 K engraftment were
90  3%, 77  5%, and 75 5%, respectively for all patients, and
94  3%, 81  5%, and 80  5%, respectively, for the 98
remission patients. Relapse rate for malignancies were 25 6% for
all patients (n  85) and 20  6% for remission patients (n  70),
and TRM were 26  4% (n  118) and 20  4% (n  98),
respectively, for the two groups at 1 year. With a median follow-up
of 268 days (range 50–1263 days), the Kaplan-Meier estimates of
1-year survival (n  118) and relapse free survival (n  86 malig-
nant subjects) for all patients are 65  5% and 50  7%, respec-
tively, and 73  5% (n  98) and 59  6% (n  70 malignant
subjects), respectively, for the remission patients. These results
demonstrate that HSCT using PD UCB are safe and effective.
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CD133-POSITIVE HEMATOPOIETIC STEM CELLS FROM A THIRD PARTY
DONOR: PRELIMINARY RESULTS
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Milla´n, I.1, Ferna´ndez, M.N.1 Hematology and Biostatistics (I.M.),
Hospital Puerta de Hierro, UAM, Madrid, Spain.
We have reported early sustained neutrophil recovery
(ANC 	 500 uL) after single unit CBT in adults by co-infusion
of low number of T-depleted mobilized hematopoietic stem
cells (MHSC) from a third party donor (TPD), selected as
CD34. TPD MHSC engraft early to be progressively replaced
by CB. We are attempting further improvement of hematopoi-
etic reconstitution by using TPD MHSC selected as CD133.
We report our results in 9 patients (6/3 M/F, median age 35,
range 19–56) with high risk hematological disease. We have
used increasing proportions (25–100%) of TPD MHSC selected
as CD133, so both CD34 and CD133 selections were done
in 4 cases and only CD133 in 5. Selections were done from
mononuclear cells apheresed after G-CSF (Clinimacs inmmu-
nomagnetic method, Miltenyi); 6 products were processed after
collection and 3 next morning. HSC were cryopreserved and
then thawed and infused on the day of CBT. Median CD133
cell recovery was 46.7 % (37–71) (&app;10% lower when both
selections were performed). CD3 depletion was adequate (4.7
logs). Mean CD3 dose was 0.53  104/kg (0.15–1.5). CD133
selection takes &app;1 hour longer than CD34 selection. Pa-
tients received a mean TPD MHSC cell dose of 2.7 106/kg
(2.2–3.9) (selected as CD133 plus CD34 or CD133 cells).
CD133CD34 cells in the ﬁnal product cannot be measured
by ﬂow ﬂuorometry. Sustained ANC 	 500/uL was achieved by
all patients (maximum cumulative incidence (MCI) 1, median 10
days, range 9–15). CB-ANC 	 500/uL was reached at 15–41
days (median 21, MCI 1). Median time to stable platelet count
	20.000/mL was 27 days (range 14–45, MCI 0.778, 95% CI
0.55–1); 40 days to 	50.000/mL (range 29–59, MCI 0.56, 95%
CI 0.31–1). All patients but one, who died on day 27, reached
full CB chimerism at 15–49 days (median 28, MCI 0.89, 95% CI
0.71–1). No cases of TPD-related GvHD, delayed CB engraft-
ment, or other adverse effects related to the use of CD133
cells were observed. Compared to cases receiving only TPD
CD34  HSC, neutrophil recovery is similar (with no major
neutropenic infections). Time to platelet recovery may be
shorter but data are not enough for statistical evaluation.
CD133 positive selection yields enough cells with adequate
CD3 cell depletion to ensure engraftment without GVHD.
Compared to CD34 selection, the procedure is longer and the
recovery lower. Factors inﬂuencing yields include high number
of total cells in the initial product, low proportion of target cells,
and delayed processing. (Grants PI04/2794 and Allostem).
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STEM CELL TRANSPLANTATION
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We have studied the properties of peripheral blood stem cell
(PBSC) mobilization, harvesting, and selection in 128 patients with
severe autoimmune diseases undergoing non-myeloablative autol-
ogous hematopoietic stem cell transplantation (HSCT). Fifty pa-
tients had a diagnosis of systemic lupus erythematosus (SLE),
43—multiple sclerosis (MS), 15—Crohn’s disease (CD),
8—scleroderma (Scl), and 12—others. Female/male ratio and
mean age (range) were 90/38 patients, and 34 (14–59) years old,
respectively. Mobilization regimen included cyclophosphamide
2g/m2 and G-CSF 5–10 mcg/kg/day. Baxter CS300 was used for
stem cell collection in 41 patients, Spectra in 78 patients, and in 9
patients both apheresis machines were utilized. The mean number
of aphereses was 1.8 (range 1–10). Patients with SLE required the
largest number of apheresis sessions (mean 2.4), compared to
patients with CD (mean 1.9), Scl (mean 1.4), MS (mean 1.3). Five
patients additionally required bone marrow harvest for collection
of adequate numbers of stem cells. One patient failed to reach
CD34 cell number of 1.0  106/kg, and therefore did not
proceed to HSCT. The mean number of CD34 cells in each
apheresis unit was 6.07  6.96  106/kg (the highest of 9.22 
8.52  106/kg was attained in patients with MS and the lowest of
3.93 4.48 106/kg, in patients with SLE). Ninety-eight patients
underwent stem cell selection with CEPRATE SC (n  18), Isolex
300iv1.12 (N  2) or Isolex 300iv2.5 (N  78) stem cell concen-
trator. The mean purity of selected products was 74.3%; mean
recovery of CD34 cells was 61.2%. T cell reduction by average
of 3.7 logs was achieved. The mean number of infused CD34
cells was 7.24  5.5  106/kg. We observed a moderate positive
correlation between peripheral blood (PB) CD34 cells/ul and PB
WBC/ul (R  0.34, P  .05), PB platelets/ul (R  0.51, P  .05)
and a strong positive correlation between PB CD34 cells/ul and
the number of CD34 cells/kg/apheresis (R  0.67, P  .05). A
weak positive correlation was seen between the number of infused
CD34cells/kg and faster WBC engraftment (ANC 	 500) and
platelet engraftment (platelet count 	 20 K). There was no ob-
served toxicity except for 1 patient with SLE who died of dissem-
inated mucormycosis 1 week after stem cell collection. Mobiliza-
tion, harvesting, and selection of PBSC in patients with severe
autoimmune diseases undergoing non-myeloablative autologous
HSCT are safe and efﬁcient.
Poster Session II
102
